Compound class:
Peptide or derivative
Comment: ALM201 is a small 23 amino acid peptide that is derived from the FK506 binding protein FKBPL. It has anti-angiogenic and anti-tumour activities [2].
|
No information available. |
Summary of Clinical Use |
ALM201 has completed Phase 1a clinical evaluation, and was granted FDA orphan drug designation for ovarian cancer in 2017 [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | Phase 1 Interventional | Almac Discovery |